Other studies at the ACR/ARHP Annual Scientific Meeting in November examined arthritis treatment, scleroderma screening.
Biosimilar Drugs Face Challenges to Reach the U.S. Market
To date, the FDA has not approved a biosimilar product. In its own discussion of the merits and obstacles to biosimilar drugs, the ACR sponsored a panel session titled, “Biosimilar Products in the U.S. Market: Fact or Fiction?” at the 2011 ACR/ARHP Annual Scientific Meeting here in November.
Information on New Drug Approvals and Medication Safety
Rheumatology-related drug safety, approvals, and what’s in the pipeline.
Letter: RA Approval for IL-1Ra
Investors convinced the executives of Synergen that they needed to evaluate IL-1Ra for a disease with a more rapid outcome. RA studies were too slow to yield a quick profit. Thus, they picked sepsis syndrome.
A Short History of Rheumatoid Arthritis Therapeutics
Or, why I chose to become a rheumatologist
Opening a New Therapeutic Window for Rheumatoid Arthritis
New targets in rheumatoid arthritis: SYK, JAK, BTK
Drug Updates: Apremilast, Belimumab, and More
Information on new approvals and medication safety
Coding Corner Question
Decembers’s Coding Challenge
Watch Those Eyes
What you need to know about Uveitis in Rheumatic Diseases
Science from our Sisters
Recommended reading from A&R and AC&R